Riccardo Canevari
Chief Executive Officer RadioPharm Theranostics
Riccardo Canevari is a biotech CEO and Board Director with over 25 years of global leadership experience across the U.S. and Europe, focused on translating scientific innovation into impactful therapies for patients and value for investors. He has led companies through all phases of growth, from concept and asset selection to Nasdaq listing, raising over AU$190 million in capital. His expertise spans oncology, radiopharmaceuticals, and precision medicine, building organizations that integrate cutting-edge science with commercial execution. Prior to leading Radiopharm Theranostics, Riccardo held senior global roles at Novartis and Advanced Accelerator Applications, supporting the launch and commercial strategies for therapies including Lutathera®, Pluvicto®, Kisqali®, and Piqray®.
Seminars
- Demonstrating strong tumor uptake and imaging performance in Trop-2–positive cancers
- Highlighting opportunities to use Trop-2 expression for patient selection and treatment planning
- Establishing Trop-2 as a promising candidate for integrated diagnostic and therapeutic strategies
- Translating diagnostic imaging biodistribution into therapeutic dose estimates and dosimetry thresholds for cycle scheduling
- Defining target expression and on-target binding criteria via pre-treatment scans to guide patient selection and reduce off-target risk
- Planning treatment cycles and follow-up intervals based on calculated organ dose limits, expected adverse-event kinetics, and recovery profiles
